Find a trial

At Icon, we offer clinical trials across various tumour types and blood disorders, allowing patients access to new and emerging advances in treatment, find a trial that might be suitable for you.


Use the search function below to find a clinical trial that may suit you and your cancer diagnosis

+ Advanced

ADG206-1001

A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects with Advanced/Metastatic Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

REFOCUS RLY-4008-101

A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

SKB264-II-06

A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Locations

Wesley

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

OP-1250-002

A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer (OP-1250-002)

Locations

Wesley, Southport

Diagnosis

Breast cancer

Open for recruitment
View Trial

SHR-A1921-I-102

A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BGB-24714-101

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

RC198-G001

A Phase 1, First-In-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Locations

Wesley

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ATRIUM ATG-018-001

A Phase 1, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

CK-301-101

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

PXS5505-MF-101

A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Locations

Adelaide (Kurralta Park)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

DB-1303-O-1001

A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors. (DB-1303-O-1001)

Locations

South Brisbane

Diagnosis

Breast cancer, Endometrial cancer

Open for recruitment
View Trial

BGB-A317-A3055-101

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

STARSTRUCK 177Lu-TLX250-001

A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and peposertib in Patients with Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ADG116-1003

A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BA3011-002

A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor

Locations

Central Building (Oncology)

Diagnosis

Lung cancer

Open for recruitment
View Trial

ASPEN-06 AT148006

A Phase 2/3 Study of ALX148 in Patients with Advanced HER2- Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Locations

Southport

Diagnosis

Gastric / gastroesophageal cancer

Open for recruitment
View Trial

ASPEN 06

A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Locations

Farrer Park

Diagnosis

Gastric / gastroesophageal cancer

Open for recruitment
View Trial

BRUIN MCL-321 / LOXO-BTK-20019

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma

Locations

Wesley, South Brisbane, Chermside, Southport, North Lakes

Diagnosis

Lymphoma – Hodgkin’s

Open for recruitment
View Trial

Viktoria-1 CELC-G-301

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Locations

Southport

Diagnosis

Breast cancer

Open for recruitment
View Trial

Viktoria-1

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Locations

Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

HERTHENA–Lung02

A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-Based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy.

Locations

Mount Alvernia

Diagnosis

Lung cancer

Open for recruitment
View Trial

VERITAC-2 C4891001

A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) VS Fulvestrant in Participants with Estrogen Receptor-Positive, HER-2-Negative Advanced Breast Cancer whose Disease Progressed after Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2)

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

SHR-2002-102

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

CS5001-101

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours, Lymphoma – B-cell Non Hodgkin’s, Lymphoma – T-Cell Non Hodgkin’s, Lymphoma – Hodgkin’s

Open for recruitment
View Trial

LM108-01-101

A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

APG-2449-OG-101

A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer

Locations

South Brisbane

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

CAPTURE BCT1901

A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

CO44194

A Phase II, Multicenter, Randomized, Double-Blind Study of RO7247669 Combined with Nab-Paclitaxel compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Locations

Adelaide (Windsor Gardens)

Diagnosis

Breast cancer

Open for recruitment
View Trial

JAVELIN Bladder Medley

A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy

Locations

Adelaide (Kurralta Park)

Diagnosis

Urothelial cancer

Open for recruitment
View Trial

INAVO121 WO43913

A Phase III, Multicenter, Randomized, Open-Label Study Evaluation the Efficacy and Safety of Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer who Progressed during or after CDK4/6 Inhibitor and Endocrine Combination Therapy

Locations

Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

SB221

A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients with Platinum-Resistant Ovarian Cancer

Locations

Adelaide (Kurralta Park), Adelaide (Windsor Gardens)

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

STELLAR 303

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Locations

Farrer Park

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

KRYSTAL-12

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Locations

Farrer Park

Diagnosis

Lung cancer

Open for recruitment
View Trial

EvoPAR-Prostate01 D9723C00001

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

Locations

Townsville, Chermside

Diagnosis

Prostate cancer

Open for recruitment
View Trial

HLX10-020-SCLC302

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Locations

Wesley

Diagnosis

Lung cancer

Open for recruitment
View Trial

ASCENT-07 GS-US-598-6168

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

Locations

Hobart, Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

BGB-A317-LBL-007-201

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer

Locations

South Brisbane

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

KEYVIBE-010 MK-7684A-010

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma

Locations

Hobart

Diagnosis

Skin cancer – melanoma

Open for recruitment
View Trial

AK104-212

A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

Locations

South Brisbane, Chermside

Diagnosis

Lung cancer

Open for recruitment
View Trial

AK112-101

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Locations

South Brisbane, Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours, Ovarian cancer

Open for recruitment
View Trial

RINGSIDE AL-DES-01

A Study of AL102 in Patients With Progressing Desmoid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Sarcoma

Open for recruitment
View Trial

BO43936

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Kidney cancer

Open for recruitment
View Trial

CA116-001 MORAb-202

A Study of MORAb-202 Versus Investigator’s Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Locations

Chermside

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

Relativity-106

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)

Locations

Farrer Park

Diagnosis

Liver cancer

Open for recruitment
View Trial

BBI-TP-3654-102

A Study of Oral TP-3654 in Patients With Myelofibrosis

Locations

Adelaide (Windsor Gardens)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

ABSK043-101

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BRIGHTLINE-1

A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Sarcoma

Open for recruitment
View Trial

AK127-101

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

AML M22

AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Locations

South Brisbane, Wesley, Chermside, Southport

Diagnosis

Leukaemia

Open for recruitment
View Trial

REGENERON_ R1979-ONC-1625

An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory follicular lymphoma

Locations

Farrer Park

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

VNC-236-101

An Open-Label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP236 Monotherapy in Subjects with Advanced Cancer

Locations

South Brisbane, Adelaide (Kurralta Park), Adelaide (Windsor Gardens)

Diagnosis

Cancer-unknown origin

Open for recruitment
View Trial

DESTINY-B12 D9673C00007

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)

Locations

Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

CLINCH / ATG-022-ST-001

An Open, Multi-center, Phase I Clinical Study of ATG-022 in Patients with Advanced/metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ALLG NBCR

Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry

Locations

Wesley

Diagnosis

Leukaemia

Open for recruitment
View Trial

BGB-A317-15025-101

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Locations

Adelaide (Windsor Gardens)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BRIGHTLINE-2 / 1403-0011

Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

LIBERATE

Clinical registry of focal low dose rate brachytherapy in men with biopsy confirmed low-intermediate risk prostate cancer (LIBERATE)

Locations

Epworth Richmond, Epworth Freemasons, Geelong

Diagnosis

Prostate cancer

Open for recruitment
View Trial

CONSOLE

Conventional or Stereotactic Radiotherapy for the palliation of non-spine bone metastases: A randomised phase III trial. (CONSOLE)

Locations

Wahroonga

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

DECREASE TROG 19.06

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Locations

Epworth Richmond

Diagnosis

Prostate cancer

Open for recruitment
View Trial

DASL-HiCaP ANZUP1801

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

Locations

Gold Coast University Hospital, Wahroonga, Gold Coast Private, Southport, Adelaide (Kurralta Park), Hobart

Diagnosis

Prostate cancer

Open for recruitment
View Trial

DREAM3R

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)

Locations

South Brisbane, Wesley, Chermside

Diagnosis

Mesothelioma

Open for recruitment
View Trial

PHI-101-001

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Locations

Wesley

Diagnosis

Leukaemia

Open for recruitment
View Trial

EXPERT BCT1601

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT)

Locations

Epworth Richmond

Diagnosis

Breast cancer

Open for recruitment
View Trial

ERUPT

External beam Radiotherapy and Urethral strictures in Prostate cancer Treatment (ERUPT)

Locations

Toowoomba

Diagnosis

Prostate cancer

Open for recruitment
View Trial

AMT-116-01

First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

AMT-151-01

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

HyperArc Registry VAR-2019-01

HyperArc Registry Study

Locations

Canberra, Greenslopes, Gold Coast Private, Maroochydore

Diagnosis

Brain cancer

Open for recruitment
View Trial

I-MAT MASC 03.18

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Locations

Hobart

Diagnosis

Skin cancer – non-melanoma

Open for recruitment
View Trial

BOREAS KRT-232-101

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Locations

South Brisbane, Wesley

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

MASTERPLAN

MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX and Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer with High Risk and Locally Advanced Disease

Locations

Gold Coast University Hospital

Diagnosis

Pancreatic cancer

Open for recruitment
View Trial

MRDR

Myeloma and Related Disease Registry

Locations

Wesley, South Brisbane, Chermside, Southport

Diagnosis

Multiple myeloma

Open for recruitment
View Trial

OP-1250-001

OP-1250-001

Locations

Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

VNC-236-101

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

SLN124-004

Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera

Locations

Adelaide (Kurralta Park)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

ESCALADE D8227C00001

Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤65 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.

Locations

South Brisbane, Wesley, Chermside, Southport

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

KRYSTAL-10

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Locations

Farrer Park

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

HARMONY R3767-ONC-2011

Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Locations

Hobart

Diagnosis

Skin cancer – melanoma

Open for recruitment
View Trial

ARTISTRY-7 ALKS 4230-007

Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Locations

Wesley

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

KEYNOTE-867 MK-3475-867

Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)

Locations

Hobart

Diagnosis

Lung cancer

Open for recruitment
View Trial

RADIANT / BAY 88-8223 / 20510

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Locations

Chermside, Wesley, South Brisbane, Adelaide (Kurralta Park)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

ASCENT-04 GS-US-592-6173

Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

ASCENT-03 GS-US-592-6238

Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

TREMOR

Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)

Locations

Epworth Richmond

Diagnosis

Neurological conditions

Open for recruitment
View Trial

HBI-8000-303

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

Locations

Wesley, Chermside, Southport, South Brisbane, North Lakes

Diagnosis

Skin cancer – melanoma

Open for recruitment
View Trial

C-POST R2810-ONC-1788

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Locations

Southport, Adelaide (Kurralta Park)

Diagnosis

Skin cancer – non-melanoma

Open for recruitment
View Trial

BGB-900-105

Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors

Locations

South Brisbane, Adelaide (Windsor Gardens)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

CAPItello-280

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Locations

Adelaide (Kurralta Park)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

COSTAR_213410

Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung)

Locations

North Lakes, Chermside, Wesley, Southport, South Brisbane

Diagnosis

Lung cancer

Open for recruitment
View Trial

KEYVIBE-006 MK-7684A-006

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer

Locations

Hobart

Diagnosis

Lung cancer

Open for recruitment
View Trial

EVOKE-02 GS-US-576-6220

Study of Sacituzumab Govitecan-hziy Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Locations

Adelaide (Windsor Gardens)

Diagnosis

Lung cancer

Open for recruitment
View Trial

BGB-A317-B167-101

Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Gastric / gastroesophageal cancer

Open for recruitment
View Trial

STELLAR-001

Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ASCEND CTC0304

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Locations

Wesley

Diagnosis

Pancreatic cancer

Open for recruitment
View Trial

ABCPro

Trial is evaluating a new online service for managing self-reported symptoms by people with advanced breast cancer.

Locations

Bowen Icon Cancer Centre

Diagnosis

Breast cancer

Open for recruitment
View Trial

TUGETHER BCT2102

Tucatinib together with Pembrolizumab and Trastuzumab: A Phase II, Two-Arm, Non-Comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab (MK-3475) and Trastuzumab in Patients with Pre-Treated Advanced HER2-Positive Breast Cancer

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial
There are no clinical trials currently available

We are always introducing new clinical trials across our international network. If you can’t find what you are looking for please don’t hesitate to speak to your doctor to learn more, or contact us here.

Search

Become a patient